Zanger UM, Turpeinen M, Klein K, Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392(6):1093–1108. https://doi.org/10.1007/s00216-008-2291-6

Article  CAS  PubMed  Google Scholar 

Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007

Article  CAS  PubMed  Google Scholar 

Wang D, Sadee W (2016) CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenet Genomics 26(1):40–43. https://doi.org/10.1097/fpc.0000000000000183

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, Stricker B, van Schaik RH (2011) Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam study. Pharmacogenet Genomics 21(12):861–866. https://doi.org/10.1097/FPC.0b013e32834c6edb

Article  CAS  PubMed  Google Scholar 

Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H (2013) The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 38(3):349–354. https://doi.org/10.2131/jts.38.349

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang W, Zhao D, Han S, Tian Z, Yan L, Zhao G, Kan Q, Zhang W, Zhang L (2015) CYP3A4*1G regulates CYP3A4 intron 10 enhancer and promoter activity in an allelic-dependent manner. Int J Clin Pharmacol Ther 53(8):647–657. https://doi.org/10.5414/cp202272

Article  CAS  PubMed  Google Scholar 

Yuan R, Zhang X, Deng Q, Wu Y, Xiang G (2011) Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta 412(9–10):755–760. https://doi.org/10.1016/j.cca.2010.12.038

Article  CAS  PubMed  Google Scholar 

He BX, Shi L, Qiu J, Zeng XH, Zhao SJ (2014) The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease. J Clin Pharmacol 54(4):462–467. https://doi.org/10.1002/jcph.229

Article  CAS  PubMed  Google Scholar 

Uesugi M, Hosokawa M, Shinke H, Hashimoto E, Takahashi T, Kawai T, Matsubara K, Ogawa K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S (2013) Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull 36(11):1814–1821. https://doi.org/10.1248/bpb.b13-00509

Article  CAS  PubMed  Google Scholar 

Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383–391. https://doi.org/10.1038/86882

Article  CAS  PubMed  Google Scholar 

Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98(1):19–24. https://doi.org/10.1002/cpt.113

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brazeau DA, Attwood K, Meaney CJ, Wilding GE, Consiglio JD, Chang SS, Gundroo A, Venuto RC, Cooper L, Tornatore KM (2020) Beyond single nucleotide polymorphisms: CYP3A5*3*6*7 composite and ABCB1 haplotype associations to tacrolimus pharmacokinetics in black and white renal transplant recipients. Front Genet 11:889. https://doi.org/10.3389/fgene.2020.00889

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, Rérolle JP, Marquet P (2006) CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 80(1):51–60. https://doi.org/10.1016/j.clpt.2006.03.012

Article  CAS  PubMed  Google Scholar 

Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, Oetting WS, Mannon RB, Remmel RP, Matas AJ, Jacobson PA (2017) Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J 17(1):61–68. https://doi.org/10.1038/tpj.2015.87

Article  CAS  PubMed  Google Scholar 

Schacter BA, Nelson EB, Marver HS, Masters BS (1972) Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. J Biol Chem 247(11):3601–3607

Article  CAS  PubMed  Google Scholar 

Chen X, Pan LQ, Naranmandura H, Zeng S, Chen SQ (2012) Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PLoS ONE 7(6):e38495. https://doi.org/10.1371/journal.pone.0038495

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee DH, Lee H, Yoon HY, Yee J, Gwak HS (2022) Association of P450 oxidoreductase gene polymorphism with tacrolimus pharmacokinetics in renal transplant recipients: a systematic review and meta-analysis. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14020261

Article  PubMed  PubMed Central  Google Scholar 

Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH (2014) Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit 36(1):71–79. https://doi.org/10.1097/FTD.0b013e31829da6dd

Article  CAS  PubMed  Google Scholar 

de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR (2011) The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12(9):1281–1291. https://doi.org/10.2217/pgs.11.77

Article  PubMed  Google Scholar 

Wang H, LeCluyse EL (2003) Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 42(15):1331–1357. https://doi.org/10.2165/00003088-200342150-00003

Article  CAS  PubMed  Google Scholar 

Kurzawski M, Malinowski D, Dziewanowski K, Droździk M (2017) Analysis of common polymorphisms within NR1I2 and NR1I3 genes and tacrolimus dose-adjusted concentration in stable kidney transplant recipients. Pharmacogenet Genomics 27(10):372–377. https://doi.org/10.1097/fpc.0000000000000301

Article  CAS  PubMed  Google Scholar 

Liu X, Shang J, Fu Q, Lu L, Deng J, Tang Y, Li J, Mei D, Zhang B, Zhang S (2022) The effects of cumulative dose and polymorphisms in CYP2B6 on the mitotane plasma trough concentrations in Chinese patients with advanced adrenocortical carcinoma. Front Oncol 12:919027. https://doi.org/10.3389/fonc.2022.919027

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aiuchi N, Nakagawa J, Sakuraba H, Takahata T, Kamata K, Saito N, Ueno K, Ishiyama M, Yamagata K, Kayaba H, Niioka T (2022) Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole. Pharmacol Res Perspect 10(2):e00935. https://doi.org/10.1002/prp2.935

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choong E, Polari A, Kamdem RH, Gervasoni N, Spisla C, Jaquenoud Sirot E, Bickel GG, Bondolfi G, Conus P, Eap CB (2013) Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol 33(3):289–298. https://doi.org/10.1097/JCP.0b013e31828f62cd

Article  CAS  PubMed  Google Scholar 

Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H (2017) A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMET™ Plus platform. Pharmacogenomics J 17(2):174–179. https://doi.org/10.1038/tpj.2015.99

Article  CAS  PubMed